Targeted delivery of toxins and enzymes by antibodies and growth factors.
Significant progress has been made in our understanding of some of the important physiological and pharmacological barriers that limit immunoconjugate efficacy. Recent successes obtained employing immunotoxins in the treatment of leukemia and lymphoma in mouse models are suggesting ways of improving clinical strategies to treat these diseases in humans.